In diabetes research, mouse and rat models are used for in vivo experiments, and quantification of insulin in serum samples under different pathophysiological conditions and after treatment with compounds is essential. There are few commercial radioimmunoassay and enzyme-linked immunosorbent assay (ELISA) assay kits to determine the rat/mouse plasma levels of insulin. However, reliability in insulin measurements using the available biological assays is a great concern. The authors report a robust, extremely sensitive electrochemiluminescence (ECL) insulin assay using the Origen technology platform. The assay performance, as judged by the Z′ value of 0.82 ± 0.03 and the signal-to-background (S/B) ratio of 133, suggests that this is a robust and reliable assay. The intra-assay and interassay variation is less than 5%. The dynamic range of detection for insulin is 5 pg to 5 ng in the ECL assays. Recovery of insulin was about 100% when different volumes of serum were spiked with exogenous insulin. These results suggest that the ECL insulin assay is an extremely sensitive, robust, nonradioactive homogeneous assay and can be used successfully to determine the insulin levels in rodent serum samples. (Journal of Biomolecular Screening 2004:62-70) 
INTRODUCTION
I NSULIN IS A 5.8-KD PEPTIDE HORMONE secreted by the β cells of the pancreas, which controls the plasma glucose concentration by stimulating glucose transport into muscle and adipose cells. Insulin is a major regulator of protein and fatty acid synthesis and also promotes cell growth and differentiation. Insulin deficiency leads to insulin-dependent (type 1) diabetes mellitus (IDDM), whereas elevated plasma insulin levels and resistance to insulin action are common in patients with non-insulin-dependent (type 2) diabetes mellitus (NIDDM), obesity, insulinoma, and some endocrine dysfunctions such as Cushing's syndrome. Insulin measurement is important in experimental investigations to study the pathophysiology of various disorders, especially diabetes. Circulating concentrations of insulin predict the development of NIDDM and IDDM and are associated with the risk of several degenerative diseases, such as coronary and peripheral vessel atherosclerosis, hypertension, and dyslipedemia.
The basic methods used in insulin measurement include bioassays, chromatographic methods such as high-performance liquid chromatography (HPLC), and mass spectrometry and immunoassays. 1 Reliability in insulin measurements using a biological assay has been a great concern, and it was found that identical serum and plasma samples measured in different laboratories by different methods produced widely disparate values. 2 Immunoassays are routinely used for insulin determinations in serum samples, whereas the chromatographic methods are tedious and require sample preparation and large volumes of samples. The immunoassays, including radioimmunoassays (RIA) using polyclonal antisera, immunoradiometric assays using 2 monoclonal antibodies, and immunoenzymometric and immunofluorometric assays, have been used to measure insulin in plasma samples. 2, 3 Two-site immunometric assays using 2 monoclonal antibodies that react with different epitopes of insulin have led to improvements in specificity and sensitivity. In the sandwich enzyme-linked immunosorbent assays (ELISAs), 1 antibody (capture antibody) is derivatized so that it binds to a solid phase and captures the antigen. The second antibody (detection antibody) is conjugated to an enzyme that can be assayed with a colored, fluorescent, or chemiluminescent substrate, and when it binds to the analyte, it can be quantitated. [3] [4] [5] [6] The ELISA assay materials are available from several commercial sources as kits, making the assay format variable, unreliable, and expensive. The ELISA protocol involves several intermediate wash steps to remove the unreacted antibodies, and improper wash techniques will contribute to errors. Additional steps, such as detection of the bound antibody-conjugate with a substrate and use of a stop reagent, are also required. Most of the ELISA assays have a limited dynamic range of detection, requiring different assay kits such as ultra-sensitive, high-sensitive, or medium-sensitive kits for samples from different physiological conditions. When using a single ELISA kit, the samples have to be diluted, or a large volume of samples have to be used to be in the range of detection. In addition, the ELISA assays are laborintensive multistep assays, and RIA assays generate large volumes of hazardous waste. To develop a homogeneous insulin assay, we previously developed a scintillation proximity assay (SPA) using protein A or IgG antibody beads (eliminating wash steps associated with ELISA-based assays), but the assay was less sensitive, with a narrow range of detection. To overcome these limitations, we evaluated a nonradioactive homogeneous assay using IGEN's Origen technology.
The Origen technology uses an electrochemiluminescence (ECL) detection system [7] [8] [9] with distinct advantages over conventional RIA and ELISA assays. An ECL assay can be designed either as a sandwich assay with 2 different monoclonal antibodies (Mabs) or as a competition binding assay with a single antibody. In the assay described here, a pair of mouse monoclonal antibodies for different epitopes of rat insulin was used in a sandwich assay to measure insulin in biological samples ( Fig. 1 ). Ruthenium (II) trisbipyridine NHS ester (ORI-tag label) was used for labeling at the primary amine group of 1 Mab and biotin-NHS-ester for labeling the second Mab. Because the 2 antibodies are directed against different epitopes, when used at optimal concentrations, they bind to insulin in the standard or sample. The entire complex is bound to the streptavidin-coated paramagnetic beads that serve as the solid phase through the biotin moiety of the antibody. The beadcomplex is carried through a flow cell, and a magnet located below the electrode in the analyzer captures the magnetic beads with the (streptavidin)-(biotin) Mab-antigen-Mab(Ru) complex with the application of the magnetic field. The antibodies not bound to the magnetic beads are washed out of the flow cell by a stream of tripropylamine (TPA) buffer. ECL is generated by the electrochemical conversion of the ORI-tag label in the presence of TPA to active red-ox states via a series of cyclic oxidation reduction steps at the electrode surface by applying an electrical potential (Fig. 2 ). The large difference in electrochemical potentials between Ru(bpy) 3 3+ and the TPA * contributes to the energy necessary for transition to the active state, which decays releasing a photon at 620 nm. During the regeneration process, each ECL active label can emit many photons, thereby enhancing the detection signal, [7] [8] [9] and the ECL signal is read in an Origen M8 Analyzer. Here, we describe an ECL sandwich immunoassay for measuring insulin in biological samples.
MATERIALS AND METHODS

Materials
Mouse monoclonal anti-rat insulin antibodies D3E7 and D6C4 for different epitopes were obtained from Research Diagnostics, Inc. (Flanders, NJ). Streptavidin agarose (S1638) and control rat serum (S7648) were from Sigma (St. Louis, MO). Streptavidincoated Dynabeads M-280, biotin LC-sulfosuccinimidyl-6hexanoate, and ORI-tag-NHS ester were purchased from IGEN International (Gaithersburg, MD). NAP-5 and PD-10 desalting columns were obtained from Amersham Pharmacia Biotech (Piscataway, NJ). The rat insulin standard (lyophilized powder cat. other fine chemicals used were of the highest purity available and obtained from Sigma.
Labeling antibodies
Monoclonal antibodies (Mabs) to different epitopes of insulin were desalted on NAP-5 prepacked G-25 disposable columns to remove azide and to equilibrate the antibody in phosphatebuffered saline (PBS) buffer. Then, 1 mg of D3E7 antibody was biotinylated with biotin-NHS ester (at a molar ratio of 20:1 biotin/ Mab) by incubating at room temperature for 1 h. About 1 mg of D6C4 antibody in 1.0 mL of PBS was ruthenylated with ORI-tag-NHS ester at a molar ratio of 8:1 (ORI-tag/Mab) by incubating at room temperature for 1 h. The reactions were quenched with the addition of 20 µL of 2 M glycine and incubated for 10 min at room temperature. The labeled antibodies were purified by loading the reaction contents onto PD-10 columns, 0.5-mL fractions were collected, the protein in the fractions was determined, and the fractions containing labeled protein were pooled, aliquoted, and stored at -20°C.
Insulin-depleted control rat serum
To improve on the reliability of the assay and to produce measurements that are directly proportional to the analyte in the samples, control rat serum was depleted of insulin. Biotinylated D3E7 Mab was coupled to streptavidin agarose beads by overnight incubation at 4°C. The beads were gently washed and incubated overnight at 5°C with 10 mL of control rat serum to remove insulin from the serum. The insulin-depleted serum was separated from the agarose beads by filtration. To minimize the matrix effects on the assay, insulin standards were diluted with insulin-free serum, and the same volumes of standards as that of plasma samples were used.
ECL rat (mouse) insulin assay
In the ECL sandwich assay, 2 anti-rat insulin Mabs-clone D6C4 and clone D3E7-that are specific for different epitopes of the rat insulin molecule were used. Mab-D6C4 was ruththenylated, and D3E7 was biotinylated. Streptavidin-coated paramagnetic beads (2.8 µ in diameter) act as the solid phase and facilitate rapid assay kinetics. Rat insulin standard was diluted in assay buffer (PBS buffer containing 1% (w/v) BSA and 0.5% (v/v) Tween-20, pH 7.5). Insulin standards covering a range of 1 pg to 20 ng per assay diluted in insulin-free serum were added in a 10-µL volume or a 10-µL insulin-free serum (blank) to wells of a Corning 96-well microplate followed by 40 µL of assay buffer to the wells. The test rat serum samples (10 µL) in duplicate and a 40-µL assay buffer were added to the other wells. Stock solutions of biotinylated antibody 3 µg/mL, ORI antibody 8 µg/mL, and streptavidin magnabeads 0.4 mg/mL were made in the assay buffer, and 25 µL of each of these was added to all the wells containing standards, blanks, and samples. The plate was sealed and incubated by gently shaking at room temperature for 2 h. At the end of incubation, 125 µL of assay buffer was added to all the wells, the contents of each well were mixed, and a 200-µL reaction was processed for ECL in an Origen M8 Analyzer.
Instrumentation
The Origen M-Series® M8/384 Analyzer detector integrates an automatic sampler, an electrochemical flow cell, a luminometer, a potentiostat, and a sample changer. The sample mixture is aspirated and drawn into an electrochemical flow cell where the paramagnetic particles are captured on the surface of the electrode within the flow cell. ORI-tag-labeled antibody not bound to the magnetic bead immune complex is washed from the flow cell by a stream of TPA assay buffer. An excited form of the ruthenium complex is formed at the surface of the electrode with the application of an electrical potential. The excited ruthenium then decays to its ground state, emitting a photon at 620 nm ( Fig. 2 ). Each active ECL label can generate several photons by the regeneration process, which are detected by a photomultiplier tube. The electrode is then washed successively by a high-pH cleaning solution and a TPA-containing assay buffer, in preparation for the next cycle.
RESULTS
To develop a homogeneous rat insulin assay in which all the reagents are added together without involving manual wash steps, we explored a sandwich ECL assay using the Origen technology platform. Evaluation of the optimal concentrations of bead and labeled antibodies is essential to obtain the highest sensitivity and signal-to-background (S/B) ratio.
Bead optimization
To determine the optimal bead concentration in the assay, streptavidin (SA)-coated magnetic beads were diluted in the assay buffer from 0.01 to 3.2 mg/mL, and 25 µL per assay was used (0.25-80 µg/assay). The signal increased with increasing amounts of the bead, and the maximum signal was observed with 10 µg bead in the assay. The signal decreased at higher bead concentration ( Fig. 3 ), and this is probably due to exceeding the capacity of the magnetic surface, where the excess bead-immunocomplex gets washed out. In all the subsequent assays, a 10-µg bead per assay was used.
Optimization of antibody concentrations
Rat insulin Mab (clone D3E7) was conjugated to biotin. To determine the optimal concentration of the biotinylated antibody in the reaction, 12.5 to 300 ng biotin antibody was used in the assay, and the ECL signal generated was measured. The ECL signal increased with the increasing concentration of the biotin antibody, with the maximum signal at about 75 and 100 ng of biotinylated antibody (Fig. 4a ), and beyond this concentration, the signal de-creased. The decrease in signal could be due to exceeding the streptavidin bead capacity in which the antigen bound to the free biotin antibody is washed out, resulting in signal reduction. Hence, 75 ng of biotinylated D3E7 antibody per assay was used in the subsequent experiments.
D6C4 Mab was ruthenylated with ORI-tag, as described in the Methods section. To determine the optimum concentration of the antibody, 2.5 to 750 ng of the ORI-tag-labeled antibody per assay was titrated in the presence of 75 ng biotinylated Mab, 10 µg streptavidin magnetic beads, and 0.5 ng rat insulin. The signal increased with increasing amounts of the ORI-tag antibody (Fig. 4b ) and did not reach saturation even at 750 ng. A reasonable signal was observed between 180 and 250 ng of the ORI-tag antibody; therefore, in all the subsequent experiments, 200 ng of the ORI-tag antibody was used.
Optimization of the standard curve for the determination of insulin in samples
When insulin was measured in different volumes of rat serum using the rat insulin standard calibration curve in buffer, there was no linearity in the sample insulin detected with increasing volumes of serum, suggesting that serum factors interfered in the assay. Insulin standard calibration curves obtained in the presence of plasma were shifted to right, with increasing volumes of serum compared to the standards run in buffer only (Fig. 5 ). This clearly shows that the serum factors reduced the signal through an unknown mechanism. To overcome the serum interference in the assay, the standards were made in the same matrix background as the samples. Rat insulin (from 0.5 to 1000 pg) was diluted in the insulin-depleted rat serum, and 40 µL of standard was used. Plasma ORI-Tag-antibody, ng To determine the optimum ORI-tag antibody concentration in the insulin electrochemiluminescence (ECL) assay, the ORI-tag-labeled antibody was titrated from 13 to 750 ng in the presence of 0.5 ng rat insulin, 75 ng biotinylated anti-insulin antibody, and 10 µg streptavidin magnetic beads in a 125-µL total reaction volume.
from Zucker rat or plasma from db/db mice was diluted in the depleted serum, and 40 µL of diluted samples (representing 5, 10, 20, 30, and 40 µL of undiluted plasma) was used in the assay. The insulin content was determined from the standard calibration curve obtained with rat insulin standards in the presence of depleted serum ( Table 1 ). The insulin content increased linearly with increasing volumes of undiluted plasma (with decreasing dilutions). Similarly, the insulin amount increased linearly with decreasing dilutions of db/db mouse plasma. The insulin concentrations in the rat plasma or mouse plasma determined at all the dilutions were very similar, with a mean of 20 ng/mL and 4.90 ng/mL, respectively. The average insulin concentration in the undiluted Zucker rat plasma was 20.15 ± 0.88 ng/mL, and the average undiluted db/ db mouse plasma insulin concentration was 4.90 ± 0.09 ng/mL.
Thus, the ECL insulin assay provides measurements that are directly proportional to the concentration of insulin in the sample.
Recovery of exogenous insulin
To determine the recovery of external insulin added in the assay, depleted rat serum (10 and 20 µL) was spiked with varying concentrations (10, 50, and 100 pg) of insulin. In another experiment, db/db mouse plasma was spiked with 100, 200, 400, and 500 pg insulin. Insulin concentrations in these samples were determined from the standard calibration curve that was obtained using 5 pg to 2 ng rat insulin in the presence of depleted serum. The recovered insulin amount (after subtracting the basal sample insulin amount) in the samples was very close (95% to 115%) to the amount of exogenously added insulin ( Table 2 ). The total recovery of added insulin in the assay indicates that the assay can accurately measure insulin in the sample throughout the working range of the calibration curve.
Dependence of signal on time of incubation
To determine the optimal incubation time for the development of the ECL signal, several concentrations of the insulin standard were incubated for different time periods after the addition of all the reagents. Although the signal can be detected in about 15 min, the signal increased slowly up to 60 min and then rapidly reached the maximum between 120 and 240 min. The signal remained stable even after overnight incubation (Fig. 6) . The insulin concentration for the half-maximal signal (EC 50 ) was about the same: 353, 364, 376, and 387 pg insulin when the signal was read after 2, 4, 5, and 16 h incubation, respectively. This suggests that the incubation periods between 2 and 16 h will produce similar results. In all the subsequent experiments, the plates were incubated for 120 min.
Insulin standard calibration curve
Insulin standards (in duplicate) ranging from 1 pg to 10 ng were incubated for 2 h with 75 ng of biotinylated insulin antibody, 200 ng of ORI-tag-labeled antibody, and 10 µg of streptavidin magnetic beads (as described in the Methods section). The insulin stan- dard curve is generated by plotting the ECL intensity (blank subtracted) value against log insulin concentrations. A sigmoidal curve was obtained with an ECL intensity range between 1400 and 450,000 relative luminescence units (RLUs) for insulin from 0.001 to 10 ng/well on a semilog plot ( Fig. 7) . When the concentration and the corresponding RLUs units were plotted on a logarithmic scale, a linear relationship was observed from 5 pg to 2.5 ng (plot not shown). The coefficient of variation (CV) at 5 and 10 pg insulin was 8% to 9%, whereas at 20 pg and higher insulin amounts, the CV was less than 5%, suggesting that the assay is sensitive enough to be able to detect lower levels of insulin. Routinely, standards ranging from 1 pg to 1 ng/well were used, in which the linear calibration curve was obtained and the insulin content in the samples could be directly derived.
Specificity of the antigen-antibody capture
To confirm that the ECL signal obtained is by the specific binding of insulin in the standard or sample to the biotin and ORI-taglabeled antibodies, as well as binding of the complex to the streptavidin magnetic bead, we carried out the ECL assay with insulin standards in the presence and absence of 10 µM d-biotin. The signal was totally abolished in the presence of biotin (Fig. 8) . Thus, biotin competed the binding of the biotin antibody to the streptavidin magnetic bead, and the biotin Mab-insulin-ORI-tag Mab complex was washed out and did not produce the ECL signal. The average biotin in the serum of normal rats is 19 nmol/L, 10 and small fluctuations in the biotin levels in the serum samples will not affect insulin determination because the same rat plasma matrix was used in the assay. These results suggest that the signal obtained in the ECL assay is due to the sandwich binding of antigen to the insulinspecific antibodies. Screening 9(1); 2004 www.sbsonline.org 67 Electrochemiluminescence Insulin Assay FIG. 7 . Standard curve for insulin assay. A stock solution of 200 ng/ mL of rat insulin was made in water, and further dilutions were made using assay buffer. Insulin standards ranging from 10 ng to 1 pg were used in a 125-µL total volume in the assay. Triplicate samples of each concentration of standards were incubated for 2 h with 75 ng of biotinylated insulin antibody, 200 ng of ORI-tag antibody, and 10 µg of streptavidin magnetic beads. Insulin standard curve is generated by plotting the electrochemiluminescence (ECL) intensity (blank subtracted) value against log insulin concentrations and fitting the data by sigmoidal fit of the Sigma plot. A sigmoidal curve was obtained with an ECL intensity range between 1400 and 450,000 relative luminescence units (RLUs) for 0.001 to 10 ng/well insulin.
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Assay performance
To evaluate the quality of this insulin assay, we assessed the assay performance by calculating the Z′ value using the following equation The Z′ factor provides a useful tool for evaluating the quality of any assay in general and indicates if the assay conditions have been optimized. An average Z′ value of 0.82 was obtained from a total of 15 of 96-well plates, consisting of several (6 to 24) data points per plate of positive controls (1 ng insulin) and an equal number of data points for negative controls (buffer only, no insulin) ( Fig. 9 ). The S/ B ratio with 1 ng insulin against buffer control was 133. In general, a Z′ value > 0.5 for an assay indicates that it is a robust assay and is suitable for HTS and automation. The Z′ value ranged from 0.75 to 0.87 for a number of experiments on different days, with an average Z′ value of 0.82. These results show that the ECL insulin assay is of high quality, and the assay is adequately optimized and is suitable for higher throughput analysis.
Intra-assay and interassay precision
The intra-assay coefficient of variation was determined using mice plasma samples containing 0.35 and 0.49 ng/mL (n = 24) in each plate. The intra-assay coefficient of variation from 5 different plate assays ranged from 1.67% to 2.33% and 1.60% to 5.03% for the 2 mice plasma samples, respectively. The interassay variation with the above samples in the 5 assays was 2.44% and 3.14%. The assay has intra-assay and interassay precision and accuracy within ±5%.
Validation of the assay
The insulin ECL assay specifically detects insulin in the plasma or serum of rodents. To further validate the insulin ECL assay, plasma samples from mice treated with statin compounds were analyzed and the results compared with ELISA assay results. Treatment with statin A decreased insulin concentration in a dosedependent manner, whereas statin B did not significantly change the insulin concentration. The insulin concentrations determined by both methods for each group of treatment were similar, agreeing with each other, and showed a similar effect of the statins tested (Table 3 ). Zucker rats were treated with antidiabetic compounds, and the serum insulin concentrations from 10 to 240 min after treatment were determined by both ECL and ELISA assays (Fig.  10) . The insulin concentration at all time points in all the animals analyzed by both methods were similar, showing very good agreement between the ECL-insulin assay and the ELISA assay, with a correlation coefficient of 0.88. These results confirm that the ECLinsulin assay described here can be used as efficiently as any commercially available ELISA assays.
DISCUSSION
Insulin is a frequently used biomarker in diabetes, and its levels are altered upon drug intervention. During drug development for diabetes targets, insulin levels in animal models can provide an early and easy measure of drug efficacy, enabling decision making in drug design and development. Analytes can be measured by chromatographic assays or immunoassays (RIA, IRMA, ELISA, EIA). Immunoassays are relatively easier, with better throughput Experiment # than chromatographic assays, as they can be run in 96-well plates.
Immunoassays are based on an antigen-antibody reaction and are unique for each analyte. Due to the specificity of antibody to analyte, immunoassays measure the analyte in biological matrices most often without any pretreatment of samples. Nonspecifc interference may be caused by substances that have physicochemical similarity to the analyte (metabolites, degradation products, and isoforms of the analyte). 12 Nonspecific interference on the antigenantibody binding reaction may also be caused by nonspecific factors such as serum proteins, anticoagulants, proteases, binding proteins, autoantibodies, anti-IgG antibodies, cations, hemolysis, hyperlipedemia, ionic strength, pH, and sample viscosity and is re-ferred to as matrix effects. Some of the nonspecific matrix interferences may be minimized by dilution with buffer containing detergents and chelating agents such as Tween-20, Triton X-100, and EDTA. If dilution fails to decrease the interference, the same sample matrix has to be applied to the calibrators (standards), and if that fails, then sample cleanup may be necessary. Antidiabetic compounds are tested in animal models (in vivo) during drug discovery, and serum insulin levels are monitored for determining the compound efficacy in preclinical models. Different sandwich ELISA assays were developed for human insulin in different laboratories; 4-6 nonetheless, not many assays are described in the literature for rodents. Commercial solid-phase immunoassays for rat insulin (midrange, ultra-sensitive-range sandwich ELISA assays, RIA assays) are available and cover a narrow range of insulin detection limits. The ELISA assay can be made either more or less sensitive, with a change in the amount of capture antibody coated on the plate, as well as the detection antibody or changing antibodies (different affinities). Using a single narrow-range ELISA kit, depending on the serum concentration of insulin, the samples have to be run more than once (diluted or use higher volumes) to be able to bring them within the range of detection. Also, these assays are heterogeneous, requiring separation and elimination of unreacted antibodies by sequential wash steps.
To develop a robust, reliable, yet simple homogeneous rat (mouse) insulin assay involving simple addition of reagents, incubation, and analysis in a plate reader, we have explored ECL technology. The ECL assay is a sandwich immunoassay with 2 Mabs directed against 2 different epitopes of rat insulin. One monoclonal antibody is ruthenylated, whereas the other one is biotinylated. The ruthenium label does not alter the solubility or immunoreactivity of the antibody. The labeled antibodies are also very stable. The as- Screening 9(1); 2004 www.sbsonline.org 69 Electrochemiluminescence Insulin Assay say involves no laborious wash steps because the analyzer performs the separation by extracting the paramagnetic particles with high precision. The entire assay requires only 1 incubation step, and the detection is rapid.
Journal of Biomolecular
In the ECL-insulin assay, nonspecific interference from the serum matrix has been eliminated by using insulin-depleted serum (by specific removal of insulin from serum by immunoaffinity chromatography) for the preparation of a standard calibration curve. The insulin amounts were inversely proportional to the dilution of the sample using a calibration curve obtained with insulin standards diluted in the insulin-depleted serum matrix. The concentration of insulin in the serum sample calculated at various dilutions was essentially the same. When serum samples were spiked with the reference standard, the observed insulin values are close to the expected values, suggesting that the spiked analyte was fully recovered, thereby validating the assay. Thus, the strategy of using the analyte-free serum matrix eliminated interference from the endogenous nonspecific factors.
The ECL assay was systematically analyzed to maximize the assay sensitivity and detection range. Optimal results were obtained using 10 µg streptavidin beads, 75 ng biotinylated antibody, and 200 ng ORI-tag-labeled antibody. The assay signal increased with time, and maximum signal was achieved by 2 to 4 h and was stable even after overnight incubation. At all the time points from 2 h to overnight, the EC 50 of the insulin standard curve remained the same (~360 pg), suggesting that even though the signal increased with time, the sensitivity of the assay remained the same.
The cost of reagents per well for the assay is very low when the reagents are developed in one's own laboratory compared to the commercial RIA and ELISA kit assays, which are available as expensive kits. If the antibodies are available, adding the biotin or ruthenium group to the antibodies is relatively easy as the coupling reaction chemistries are well established. The ECL assay has a wide dynamic range over 3 orders, so that unknown samples containing as low as 5 pg to as high as 10 ng insulin (in the sample assay volume) could be analyzed in the serum without the need to dilute the sample. The assay involves no radioisotopes, eliminating disposable problems. The assay can be completely automated, and the M-Series® M8/384 Analyzer is capable of reading 384-well plates, thus increasing the throughput immensely and reducing the reagent costs further. The ECL-insulin assay described here is a sensitive, very robust, reliable, homogeneous, and inexpensive nonradioactive assay compared to the traditional ELISA or radioimmunoassays.
